Drug Profile
Abiraterone oral - Bukwang Pharmaceuticals
Alternative Names: SOL-804Latest Information Update: 02 Feb 2023
Price :
$50
*
At a glance
- Originator Solural Pharma
- Developer Bukwang Pharmaceutical; Solural Pharma
- Class Antiandrogens; Antineoplastics; Phenanthrenes; Pyridines; Small molecules
- Mechanism of Action CYP17A1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Prostate cancer
Highest Development Phases
- Phase I Prostate cancer
Most Recent Events
- 25 Feb 2022 Bukwang Pharmaceuticals completes a phase-I trial in Prostate cancer (Metastatic disease, Hormone refractory) in South Korea (PO)
- 21 Oct 2021 Phase-I clinical trials in Prostate cancer (Metastatic disease, Hormone refractory) in South Korea (PO)
- 21 Oct 2021 Ministry of Food and Drug Safety of Korea approves clinical trial application (CTA) for Abiraterone oral in castration-resistant prostate cancer